Fourth quarter and full year 2019


Sanofi delivers strong 2019 business EPS growth of 6.8% at CER

Fourth quarter and full year 2019 results were reviewed by management during a conference call with the financial community. The presentation was followed by a Q&A session.

I am encouraged by the fourth quarter results which position Sanofi to deliver on our new strategic priorities.

Paul Hudson

Chief Executive Officer



Clinical trials appendix

Press release

Q4 and full year 2019 income statements, cash flow statements, balance sheet

Q4 and full year 2019 net sales by GBU, franchise, geographic region and product

Download infographic

Pre-quarterly results communication